It looks like another health problem has popped up with some of the weight loss drugs so many women of reproductive age are now taking. This time menstrual related events, including heavy menstrual bleeding, blood clots, and frequency of menstrual bleeding.
Researchers looked at data in the FDA Adverse Event Reporting System for 3 weight loss drugs (Semaglutide, Tirzepatide, and Liraglutide), which are glucagon-like peptide-1 receptor agonists. They found that females aged 12 to 55 years (reproductive age) reported problems with 2 of the weight-loss drugs. Semaglutide had the most adverse reports: heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, infrequent menstrual periods (oligomenorrhea), and cycles without ovulation (anovulatory cycles). Tirzepatide had reports of intermenstrual bleeding and menstrual clots, and Liraglutide had by far the fewest adverse reports ("produced no significant signals").
From Medscape: Menstrual Clots and Heavy Bleeding Linked to Popular Weight-Loss Drugs
GLP-1 receptor agonists (RAs), particularly semaglutide, are associated with disproportionate reporting of menstrual adverse events including heavy bleeding, intermenstrual bleeding, and menstrual clots in reproductive-aged female patients. Tirzepatide showed signals for intermenstrual bleeding and menstrual clots. ...continue reading "Some Weight Loss Drugs Can Result In Menstrual Related Problems"